Articles tagged with: Velcade
NewsFlash »
European Medicines Agency Approves Addition Of Survival Data To Velcade Prescribing Information – On June 15, Janssen-Cilag announced that the European Medicines Agency approved the addition of data to the prescribing information for Velcade (bortezomib) showing that Velcade extends survival in newly diagnosed multiple myeloma patients. Results of an international Phase 3 study showed that the combination therapy of Velcade, melphalan (Alkeran), and prednisone elicits significantly higher complete response and overall survival rates among patients than melphalan and prednisone alone (see related Beacon news). For more information, please see the Janssen-Cilag press release.
IMF Holds Inaugural Myeloma Summit Meeting – The International Myeloma Foundation (IMF) invited leading myeloma experts to speak about the future of multiple myeloma care and treatment at their first summit meeting in North Hollywood, CA. The summit took place on the heels of the American Society of Clinical Oncology’s annual meeting. Topics for discussion included the use and timing of stem cell transplants, treatment goals, and the management of peripheral neuropathy (nerve damage to the extremities). The summit’s working group will issue consensus statements in the near future to guide treatment and further clinical trials. For more information, please read the IMF press release.
Phase 1/2b Study Of Arno Therapeutics’ Myeloma Drug Candidate AR-42 Treats First Patient – Arno Therapeutics announced treatment of the first patient with AR-42 in a Phase 1/2b study evaluating the drug for the treatment of advanced multiple myeloma, chronic lymphocytic leukemia, and lymphoma. Researchers will evaluate the drug’s safety, activity, and dosage limits. For more information, please see the Arno Therapeutics press release and the clinical trial description.
NCI Begins Phase 2 Study Of AZD6244 In Relapsed/Refractory Myeloma Patients – The National Cancer Institute (NCI) is launching a Phase 2 trial of AZD6244, a molecule that inhibits biochemical processes important to the survival of myeloma cells. The study is evaluating AZD6244 as a treatment for relapsed and refractory multiple myeloma. For more information or to participate in the trial, please contact the research nurse for this study, Mary Ann Yancey, at (301) 435-9227 or , or visit the clinical trial Web page.
News»
Preliminary results from two ongoing clinical trials suggest that elotuzumab in combination with either Velcade (bortezomib) or Revlimid (lenalidomide) plus low-dose dexamethasone (Decadron) is effective and well-tolerated in patients who have relapsed or are resistant (refractory) to previous myeloma treatment. The findings were presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
Elotuzumab is a new drug being developed by Facet Biotech and Bristol-Myers Squibb as a potential treatment for multiple myeloma. It selectively targets proteins that are on the surface of …
News»
Results of a Phase 3 trial showed that the addition of thalidomide (Thalomid) to Velcade (bortezomib), melphalan (Alkeran), and prednisone (referred to as VMPT), followed by long-term treatment with Velcade and thalidomide (VT), may become the new standard of care for elderly multiple myeloma patients. The results were presented by Dr. Antonio Palumbo of the University of Turin, Italy, on June 6 at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
Dr. Palumbo and his colleagues compared VMPT followed by VT maintenance, which they hypothesized …
News»
Significant advances have been made in the treatment of multiple myeloma since the introduction of thalidomide (Thalomid), Revlimid (lenalidomide), and Velcade (bortezomib). Combinations of these “novel agents” have significantly improved response rates and survival rates with better safety profiles than stem cell transplants, leading researchers and patients to ask whether the use of transplants is necessary given the efficacy of the novel agents.
Two studies that are investigating whether novel agents are as effective, or possibly more effective, than an autologous stem cell transplant (ASCT) were presented June …
News»
Many multiple myeloma patients are afflicted by tingling and pain in the hands, arms, feet, and legs (known as peripheral neuropathy). Treatments for myeloma can make this neuropathy worse. Dr. Paul Richardson of the Dana-Farber Cancer Institute discussed the prevention and management of peripheral neuropathy (PN) during an education session on June 7 at the annual American Society of Clinical Oncology (ASCO) meeting.
Dr. Richardson explained that myeloma, itself, causes nerve damage that leads to the pain and tingling. Up to 20 percent of patients experience some PN prior to treatment.
Myeloma …
News»
An ongoing Phase 2 trial of carfilzomib has demonstrated that carfilzomib may be effective in treating relapsed/refractory multiple myeloma patients, including patients who are resistant to or relapsed after Velcade (bortezomib) treatment. The results were presented by Dr. Ravi Vij of Washington University in St. Louis at the annual American Society of Clinical Oncology (ASCO) meeting in Chicago on June 5.
“Single agent carfilzomib has demonstrated significant activity in relapsed/refractory myeloma,” said Dr. Vij during his presentation.
Carfilzomib, developed by Onyx Pharmaceuticals, is a new drug currently being investigated …
News»
The combination treatment of reduced-dose Velcade (bortezomib), thalidomide (Thalomid), and dexamethasone (Decadron), abbreviated vTD, appears to be a safe and effective induction treatment for newly diagnosed multiple myeloma patients prior to stem cell transplantation.
The combination treatment yielded higher complete and partial remission rates, and fewer and less severe side effects, than treatment with standard dose Velcade plus dexamethasone (VD).
The vTD vs. VD findings were presented by Dr. Philippe Moreau of the University Hospital in Nantes, France, at the American Society of Clinical Oncology (ASCO) annual meeting in …